Silo pharma announces pipeline prioritization for 2024 targeting mental health, chronic pain, and neurology

Preparing pre-investigational new drug application for lead drug program spc-15 company plans to pursue fda streamlined 505(b)(2) pathway for clinical drug development sarasota, fl, feb. 01, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. the company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.
SILO Ratings Summary
SILO Quant Ranking